EP4558139A1 - Combination comprising a ggt1 inhibitor and a cysltr1 antagonist and use thereof in the treatment of invasive stages of cancer - Google Patents

Combination comprising a ggt1 inhibitor and a cysltr1 antagonist and use thereof in the treatment of invasive stages of cancer

Info

Publication number
EP4558139A1
EP4558139A1 EP23753962.2A EP23753962A EP4558139A1 EP 4558139 A1 EP4558139 A1 EP 4558139A1 EP 23753962 A EP23753962 A EP 23753962A EP 4558139 A1 EP4558139 A1 EP 4558139A1
Authority
EP
European Patent Office
Prior art keywords
ggt1
cells
cysltrl
colorectal cancer
invasive
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
EP23753962.2A
Other languages
German (de)
French (fr)
Inventor
Katarzyna Ewa SOBIERAJSKA
Wojciech Micha CISZEWSKI
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ciszewski Wojciech Michal
Uniwersytet Medyczny w Lodzi
Original Assignee
Ciszewski Wojciech Michal
Uniwersytet Medyczny w Lodzi
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ciszewski Wojciech Michal, Uniwersytet Medyczny w Lodzi filed Critical Ciszewski Wojciech Michal
Publication of EP4558139A1 publication Critical patent/EP4558139A1/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/655—Azo (—N=N—), diazo (=N2), azoxy (>N—O—N< or N(=O)—N<), azido (—N3) or diazoamino (—N=N—N<) compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Definitions

  • Combination comprising a GGT1 inhibitor and a CysLTRl antagonist and use thereof in the treatment of invasive stages of cancer.
  • the subject of the present invention is a combination comprising a GGT1 inhibitor and a CysLTRl antagonist and the use thereof in the treatment of invasive stages of cancer by inhibiting their invasive abilities (abilities to form metastases).
  • Leukotrienes known as lipid mediators of inflammation, are delivered from the 5- lipoxygenase-catalyzed oxygenation of arachidonic acid and are secreted by the ABCC1 (MRP1) transporter into the extracellular matrix (ECM) as a leukotriene C4 (LTC4).
  • LTC4 binds preferentially to the cysteinyl leukotriene receptor 2 (CysLTR2). Moreover, it can be converted to leukotriene D4 (LTD4) by gamma-glutamyltransferase 1 (GGT1), an extracellular enzyme anchored to the plasma membrane of cells.
  • LTD4 preferentially binds to the cysteinyl leukotriene receptor 1 (CysLTRl) located in the cancer cell membrane.
  • CysLTRl cysteinyl leukotriene receptor 1
  • the present patent application demonstrates that leukotriene is responsible for an increase in the invasiveness of colorectal cancer. Moreover, it was observed (Fig. 1) that the level of secreted leukotriene is higher in colorectal cancer cell lines isolated from invasive tumor stages, and that the extracellular addition of leukotriene to colorectal cancer cell lines isolated from pre-invasive tumor stages increases their invasive capacity.
  • the present patent application demonstrates for the first time that inhibition of the GGT1 protein activity leads to the differentiation of colorectal cancer cells. It was observed (Fig. 2) that the inhibition of the GGT1 protein activity is accompanied by an increase of the mucin 2 (MUC2) level, which is a marker of differentiation of colorectal cancer cells [6,7], A similar effect was observed when the GGT1 protein level was reduced by silencing the GGT1 gene expression (Fig. 3). Moreover, it was observed (Fig. 3) that an increase in the GGT1 level correlates with the degree of invasiveness of colorectal cancer, i.e., the GGT1 level increases in the colorectal cell lines isolated from the advanced stages of tumor development.
  • MUC2 mucin 2
  • the present patent application demonstrates that inhibition of CysLTRl using its antagonists inhibits the invasive abilities of colorectal cancer. It should be emphasized that the applied doses of antagonists did not cause an increase in MUC2 level, i.e., they did not induce an increase in the differentiation of colorectal cancer cells (fig. 4).
  • the present patent application demonstrates, for the first time, that the simultaneous inhibition of the GGT1 protein activity and the inhibition of CysLTRl simultaneously leads to differentiation of the cells and inhibition of the invasive abilities of the colorectal cancer cells characterized by an increased ability to metastasize (fig. 5).
  • GGT1 protein inhibitors such as acivicin (ACV) or 6-diazo-5-oxo-L-nor-leucine and CysLTRl antagonists such as montelukast or zafirlukast in cancer therapies is known in the art.
  • Applications EP3328827 and US5695751 disclose prodrugs such as acivicin and 6- diazo-5-oxo-L-nor-leucine for cancer treatment.
  • Applications EP2990056 and EP3585809 disclose CysLTRl antagonists for use in the treatment of cancer, including montelukast and zafirlukast.
  • EP2945644 discloses the use of acivicin in treating colorectal cancer and, more specifically, for preventing metastasis or recurrence of the disease.
  • EP3923936 describes the use of a pharmaceutical composition comprising zafirlukast for the treatment of tumors such as colorectal cancer.
  • a combination comprising a GGT1 protein inhibitor and a CysLTRl antagonist has not yet been described in the prior art.
  • the mentioned inhibitors and antagonists are only applicable as cytotoxic agents. Blocking the GGT1 protein activity by inhibiting the conversion of LTC4 to LTD4 reduces the ability of the latter to induce the invasive capacity of cancer cells.
  • the inventors showed that the use of GGT1 inhibitors, acivicin or 6-diazo-5-oxo-L-nor-leucine, resulted in an increase in MUC2, which is a marker of colorectal cancer cell differentiation. Furthermore, they also showed that inhibiting the conversion of LTC4 to LTD4 by reducing the GGT1 protein level utilizing siRNA increases MUC2, which promotes cell differentiation. It follows directly from this that any factor leading to reduction the level or activity of the GGT1 protein will also induce the differentiation of cancer cells.
  • GGT1 inhibitors acivicin or 6-diazo-5-oxo-L-nor-leucine
  • CysLTRl antagonists montelukast or zafirlukast
  • the application of the combination comprising the GGT1 inhibitor and the CysLTRl antagonist causes: (a) on the one hand, inhibition of the pathway responsible for inducing the cell invasiveness (by blocking the interaction of LTD4 and CysLTRl), (b) on the other hand, a stimulation of cell differentiation, i.e., cell transformation to a less advanced stage (by increasing the LTC4 level, and consequently stimulating the LTC4- CysLTR2 interaction).
  • the subject of the invention is a combination comprising a gamma-glutamyltransferase 1 (GGT1) protein inhibitor and a cysteinyl type 1 receptor (CysLTRl) antagonist.
  • GTT1 gamma-glutamyltransferase 1
  • CysLTRl cysteinyl type 1 receptor
  • the GGT1 protein inhibitor is selected from the group comprising: acivicin, 6-diazo- 5-oxo-L-nor-leucine, azaserine, OU749, GGsTop, GGTI-DU40 and its analogues, 26S -amino- 4-azi do-butanoic acid, y-phosphono monoester of glutamate and its analogues, y-phosphono diester of glutamate and its analogues, L-ABBA and its analogues, glutathione-analogous peptidyl phosphorus esters, phospho-glutathione ACPB analogues.
  • CysLTRl antagonist is selected from the group comprising: montelukast, zafirlukast and pranlukast.
  • the GGT1 protein inhibitor is selected from acivicin and 6-diazo-5-oxo-L- norleucine
  • the CysLTRl antagonist is selected from montelukast and zafirlukast.
  • Further subject of the invention is the combination according to the invention for use in the treatment of invasive stages of cancer.
  • the cancer is colorectal cancer.
  • treatment is a supportive treatment in chemotherapy or radiotherapy.
  • Fig. 1 The effect of leukotriene on the invasiveness of colorectal cancer cells.
  • Fig. 2 The effect of GGT1 inhibitors on modulating the differentiation process of colorectal cancer cells and their invasion abilities.
  • Colorectal cancer cells isolated from patients with different colon cancer invasive stages were treated with IpM of GGT1 inhibitors: ACV (acivicin) or DON (6-diazo-5-oxo-L-norleucine) for 48 hours, followed by a determination of (A) the level of the mucin 2 (MUC2) which is a marker of differentiation of colorectal cancer cells, (B) the ability of the cells to invade.
  • Fig. 3 The effect of reducing the GGT1 protein level on the differentiation of colorectal cancer cells.
  • GGT1 was downregulated with siRNA in colon cancer cells with different invasiveness properties, followed by a determination of the level of mucin 2 (MUC2), which is a marker of differentiation of colorectal cancer cells.
  • MUC2 mucin 2
  • Fig. 4 The effect of CysLTRl antagonists on modulating colon cancer cells invasion abilities and their differentiation.
  • Colorectal cancer cells isolated from patients with different colon cancer invasive stages were treated with lOpM of CysLTRl antagonists: MON (montelukast) or ZAF (zafirlukast) for 48 hours, followed by a determination of (A) the ability of the cells to invade, (B) the level of the mucin 2 (MUC2) which is a marker of differentiation of colorectal cancer cells.
  • Fig. 5 The effect of the simultaneous use of the GGT1 inhibitors and the CysLTRl antagonists on modulating the differentiation process of colorectal cancer cells and their invasion abilities.
  • Colorectal cancer cells isolated from patients with different colon cancer invasive stages were treated with IpM of ACV (acivicin) alone, or in combination with lOpM of MON (montelukast) or ZAF (zafirlukast); or IpM of DON (6-diazo-5-oxo-L-norleucine) alone, or in combination with lOpM of MON (montelukast) or ZAF (zafirlukast) for 48 hours, followed by a determination of (A) the level of the mucin 2 (MUC2) which is a marker of differentiation of colorectal cancer cells, (B) the ability of the cells to invade.
  • the cells lines were cultured as a monolayer and maintained in DMEM with GlutaMAXTM supplemented with 10% (v/v) fetal bovine serum (FBS), penicillin (100 U/mL), and streptomycin (100 pg/mL) in an incubator under standard conditions (temperature of 37°C, CO2 concentration of 5%, relative humidity of 85%),). Cells were cultured in a logarithmic growth phase and preventing them from reaching of confluence. The protein level in the cell lines was estimated by the Western Blot technique.
  • siRNA interfering RNA
  • Xfect® Reagent from TakaraBio according to the manufacturer's instructions.
  • the leukotriene level was analyzed by the commercially available ELISA assay (Leukotriene C4 ELISA Kit) according to the manufacturer's instructions.
  • the invasive potential of the studied cell lines was determined based on an analysis of the ability of the cells to transmigrate to a chemoattractant (20% FBS) through a Matrigel-covered membrane with 8.0 pm pores.
  • the ability of the cells to differentiate was determined based on investigating the changes in the level of MUC2 (a marker of differentiation of colorectal cancer cells) by immunofluorescence staining.
  • the cells were washed with PBS, fixed (4% formaldehyde in a PHEM buffer, 20 min at RT), permeabilized (0.1% Triton X-100 in a PHEM buffer, 5 min at 4°C), and then labelled with antibodies (incubated with mucin-2-recognizing antibodies, 2h at 37°C; then with secondary antibodies conjugated to the Alexa488 fluorescent dye for Ih at RT).
  • the staining was visualized with EVOS FLoid Imaging Station and analyzed using Imaged software.
  • Example 1 Testing the effect of leukotriene on invasive abilities induction in colorectal cancer cells.
  • the cells were seeded onto a 6-well plate, and after a 24-hour incubation, the culture medium was changed to a fresh one. After a 48-hour culture under standard conditions (temperature of 37°C, CO2 concentration of 5%, relative humidity of 85%), the level of the leukotriene secreted into the medium was measured by the ELISA assay.
  • LoVo cells isolated from a metastatic colorectal cancer (Dukes' D Class), secreted about 8 times more leukotriene than the SW620 cells, which had been isolated from the lymph node (Dukes' C Class), as shown in Fig. 1A.
  • the effect of leukotriene on inducing the invasiveness in the SW620 cells was determined.
  • Example 2 Testing the effect of the inhibition of the GGT1 protein activity on the differentiation of colorectal cancer cells.
  • the cells were seeded onto a 6-well plate, and after a 24-hour incubation, the culture medium was changed to a fresh one. Then, cells were treated with IpM of acivicin or 6-diazo- 5-oxo-L-norleucine and after a 48-hour of incubation, an immunocytochemical assay of the level of MUC2 was performed as described above. The results are shown in Fig. 2A.
  • GGT1 inhibition by acivicin resulted in a 4- and 6,5-fold increase in MUC2 for SW620 and LoVo, respectively.
  • 6-diazo-5-oxo-L-norleucine caused a 2.7- and 11.1-fold increase in MUC2 for SW620 and LoVo, respectively.
  • Example 3 Testing the effect of the inhibition of the GGT1 protein activity on the invasiveness of colorectal cancer cells.
  • the cells were seeded onto a 6-well plate, and after a 24-hour incubation, the culture medium was changed to a fresh one. Then, cells were treated with IpM of acivicin or 6-diazo- 5-oxo-L-norleucine, and after a 48-hour of incubation, the invasion potential of studied cell lines was estimated, as described above. The results are shown in Fig. 2B. None of the tested inhibitors affected the invasive potential of the studied cells.
  • Example 4 Testing the effect of reducing the GGT1 protein level on the differentiation of colorectal cancer cells.
  • the GGT1 protein level was determined in colorectal cancer cells isolated from patients with different colon cancer invasive stages: SW620 (a low invasiveness potential) and LoVo (a high invasiveness potential). It was observed (Fig. 3 A) that the GGT1 protein level was higher in the cells with a high invasiveness potential (LoVo).
  • the cells were seeded onto a 6-well plate, and after a 24-hour incubation, the culture medium was changed to a fresh one and the GGT1 gene expression was silenced for 48 hours by the small interfering RNA technique as described above.
  • the silencing efficiency of GGT1 was about 80% (Fig. 3B).
  • the MUC2 level was determined immunocytochemically, as described above.
  • the GGT1 downregulation increased the MUC2 level by 3.7-fold and 11.3-fold in SW620 and LoVo, respectively (Fig. 3C).
  • Example 5 Testing the effect of the CysLTRl antagonists on the invasiveness of colorectal cancer cells.
  • the cells were seeded onto a 6-well plate, and after a 24-hour incubation, the culture medium was changed to a fresh one. Then, cells were treated with 10 pM of CysLTRl antagonists: montelukast or zafirlukast and after a 48-hour of incubation the invasion potential of studied cell lines was estimated, as described above. The results are shown in Fig. 4A. Both antagonists showed a similar effect against LoVo, resulting in a nearly 8-fold decrease in the invasion abilities of cells. None of the tested inhibitors affected the invasive potential of SW620 cells.
  • Example 6 Testing the effect of the CysLTRl antagonists on the differentiation of colorectal cancer cells.
  • the cells were seeded onto a 6-well plate, and after a 24-hour incubation, the culture medium was changed to a fresh one. Then, cells were treated with 10 pM of CysLTRl antagonists: montelukast or zafirlukast and after a 48-hour of incubation, an immunocytochemical assay of the level of MUC2 was performed, as described above. The results are shown in Fig. 4B. None of the tested antagonists affected the MUC2 level in the studied cell lines.
  • Example 7 Testing the effect of the simultaneous use of the GGT1 protein inhibitors and the CysLTRl leukotriene receptor antagonists on the differentiation of colorectal cancer cells and on the inhibition of the invasiveness of colorectal cancer cells.
  • the cells were seeded onto a 6-well plate, and after a 24-hour incubation, the culture medium was changed to a fresh one. Then, cells were treated with IpM of acivicin (GGT1 inhibitor) alone or in combination with a 10 pM of CysLTRl antagonist, montelukast or zafirlukast; or with IpM of 6-diazo-5-oxo-L-norleucine (GGT-1 inhibitor) alone or in combination with a 10 pM of CysLTRl antagonist, montelukast or zafirlukast. After a 48-hour incubation, an immunocytochemical assay of the level of MUC2 and the invasion potential of studied cell lines were estimated, as described above. The results are shown in Fig. 5.
  • the mixture of the GGT1 protein inhibitor - acivicin together with the CysLTRl antagonist: montelukast or zafirlukast was observed to cause the level of MUC2 in the treated cells to increase to the level which was observed in the case of the use of acivicin alone.
  • the CysLTRl antagonist montelukast or zafirlukast
  • a 2.7- and 4.5-fold reduction in the invasive potential of the cells were observed for the combination of acivicin with montelukast and zafirlukast, respectively.
  • no change in the effect on the invasive potential of SW620 cells was observed after using the combination of acivicin with montelukast or zafirlukast.
  • acivicin alone did not affect the invasive potential of the cells.
  • a similar level of change as for the combination of acivicin with montelukast or zafirlukast was observed for the mixture of another GGT1 protein inhibitor, 6-diazo-5-oxo-L-nor-leucine together with the CysLTRl antagonist montelukast or zafirlukast.

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Oncology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

The subject of the present invention is a combination comprising a GGTI protein inhibitor and a CysLTRl receptor antagonist and use thereof in the treatment of invasive stages of cancer. The GGTI protein inhibitor is preferably acivicin or 6-diazo-5-oxo-L-norleucine; the CysLTRl receptor antagonist is preferably montelukast or zafirlukast.

Description

Combination comprising a GGT1 inhibitor and a CysLTRl antagonist and use thereof in the treatment of invasive stages of cancer.
Description of the invention
The subject of the present invention is a combination comprising a GGT1 inhibitor and a CysLTRl antagonist and the use thereof in the treatment of invasive stages of cancer by inhibiting their invasive abilities (abilities to form metastases).
Leukotrienes, known as lipid mediators of inflammation, are delivered from the 5- lipoxygenase-catalyzed oxygenation of arachidonic acid and are secreted by the ABCC1 (MRP1) transporter into the extracellular matrix (ECM) as a leukotriene C4 (LTC4). LTC4 binds preferentially to the cysteinyl leukotriene receptor 2 (CysLTR2). Moreover, it can be converted to leukotriene D4 (LTD4) by gamma-glutamyltransferase 1 (GGT1), an extracellular enzyme anchored to the plasma membrane of cells. LTD4 preferentially binds to the cysteinyl leukotriene receptor 1 (CysLTRl) located in the cancer cell membrane. Previous epidemiological studies on the development of colorectal cancer have shown a relationship between the level of cysteinyl receptor expression and the prognosis and predictable survival of the patient. In particular, an increased CysLTRl level is observed in patients with advanced cancer, and an elevated CysLTR2 level characterizes morphologically differentiated cancers observed in the pre-invasive stages of tumor development [1,2]. At the same time, it should be mentioned that morphologically differentiated cancers respond more effectively to the chemotherapeutic agents used in anti -cancer therapy [3,4], Therefore, the prognosis for patients with elevated CysLTRl levels is worse than for patients with elevated CysLTR2 levels. Moreover, activation of CysLTR2 has been found to lead to the differentiation of colorectal cancer cells. This data suggests that the balance between these two receptors is essential for tumor progression and the course of the disease [5], It also seems that preventing the dedifferentiation of tumor cells or inducing their re-differentiation will increase the percentage of patients cured. [3,4],
The present patent application demonstrates that leukotriene is responsible for an increase in the invasiveness of colorectal cancer. Moreover, it was observed (Fig. 1) that the level of secreted leukotriene is higher in colorectal cancer cell lines isolated from invasive tumor stages, and that the extracellular addition of leukotriene to colorectal cancer cell lines isolated from pre-invasive tumor stages increases their invasive capacity.
The present patent application demonstrates for the first time that inhibition of the GGT1 protein activity leads to the differentiation of colorectal cancer cells. It was observed (Fig. 2) that the inhibition of the GGT1 protein activity is accompanied by an increase of the mucin 2 (MUC2) level, which is a marker of differentiation of colorectal cancer cells [6,7], A similar effect was observed when the GGT1 protein level was reduced by silencing the GGT1 gene expression (Fig. 3). Moreover, it was observed (Fig. 3) that an increase in the GGT1 level correlates with the degree of invasiveness of colorectal cancer, i.e., the GGT1 level increases in the colorectal cell lines isolated from the advanced stages of tumor development. As a result, more effective conversion of LTC4 to LTD4 occurs in the invasive cells, and thus LTD4 can bind preferentially to CysLTRl. When GGT1 is inhibited, the conversion of LTC4 to LTD4 is blocked and the free LTC4 pool can preferentially bind to the CysLTR2 receptor. It should be emphasized that the investigated doses of GGT1 inhibitors did not inhibit the invasive capacity of colorectal cancer (fig. 2).
The present patent application demonstrates that inhibition of CysLTRl using its antagonists inhibits the invasive abilities of colorectal cancer. It should be emphasized that the applied doses of antagonists did not cause an increase in MUC2 level, i.e., they did not induce an increase in the differentiation of colorectal cancer cells (fig. 4).
The present patent application demonstrates, for the first time, that the simultaneous inhibition of the GGT1 protein activity and the inhibition of CysLTRl simultaneously leads to differentiation of the cells and inhibition of the invasive abilities of the colorectal cancer cells characterized by an increased ability to metastasize (fig. 5).
The use of GGT1 protein inhibitors, such as acivicin (ACV) or 6-diazo-5-oxo-L-nor-leucine and CysLTRl antagonists such as montelukast or zafirlukast in cancer therapies is known in the art. Applications EP3328827 and US5695751 disclose prodrugs such as acivicin and 6- diazo-5-oxo-L-nor-leucine for cancer treatment. Applications EP2990056 and EP3585809 disclose CysLTRl antagonists for use in the treatment of cancer, including montelukast and zafirlukast. EP2945644 discloses the use of acivicin in treating colorectal cancer and, more specifically, for preventing metastasis or recurrence of the disease. EP3923936 describes the use of a pharmaceutical composition comprising zafirlukast for the treatment of tumors such as colorectal cancer. However, a combination comprising a GGT1 protein inhibitor and a CysLTRl antagonist has not yet been described in the prior art. Moreover, the mentioned inhibitors and antagonists are only applicable as cytotoxic agents. Blocking the GGT1 protein activity by inhibiting the conversion of LTC4 to LTD4 reduces the ability of the latter to induce the invasive capacity of cancer cells. Simultaneous use of the CysLTRl antagonist will prevent the remaining LTD4 pool from binding to the receptor, thus blocking the path of metastasis. On the other hand, an increase of LTC4 level will result in an increased possibility of binding this form of leukotriene to the CysLTR2 receptor. Therefore, it will cause re-differentiation of tumor cells, thus reverting it to earlier stages of development more sensitive to the effects of standard chemotherapy.
In their studies on colorectal cancer cell lines, the inventors showed that the use of GGT1 inhibitors, acivicin or 6-diazo-5-oxo-L-nor-leucine, resulted in an increase in MUC2, which is a marker of colorectal cancer cell differentiation. Furthermore, they also showed that inhibiting the conversion of LTC4 to LTD4 by reducing the GGT1 protein level utilizing siRNA increases MUC2, which promotes cell differentiation. It follows directly from this that any factor leading to reduction the level or activity of the GGT1 protein will also induce the differentiation of cancer cells. In conclusion, it has been shown that the inhibition of the GGT1 protein activity, resulting in an increase in the LTC4 concentration, leads to the differentiation of tumor cells and the transition of the tumor to a pre-invasive state (stimulation of the CysLTR2-dependent pathway) [2,5,8], In addition, it was shown that using CysLTRl antagonists (montelukast or zafirlukast) decreased the invasive capacity of cells. At the same time, it should be noted that the antagonists in the doses used did not exhibit anti-proliferative properties against colorectal cancer cells. Therefore, the observed inhibition of invasiveness is not a consequence of the anti -proliferative or cytotoxic effect of the compounds used. Based on the above data, it was found that each of these compounds can lead to the inhibition of the invasive capacity of cells.
Moreover, in cells with a higher invasive potential, the simultaneous use of GGT1 inhibitors (acivicin or 6-diazo-5-oxo-L-nor-leucine) and CysLTRl antagonists (montelukast or zafirlukast) leads to both an increase of MUC2, therefore the induction of cell differentiation, as well as the inhibition of the invasive abilities of colorectal cancer cells. What is important, in addition to acivicin and 6-diazo-5-oxo-L-nor-leucine such compounds as: azaserine, OU749, GGsTop, GGTI-DU40 and its analogues, 2 (S) -ami no-4-azi do-butanoic acid, y-phosphono monoester of glutamate and its analogues, y-phosphono diester of glutamate and its analogues, L-ABBA and its analogues, glutathione-analogous peptidyl phosphorus esters, phosphoglutathione ACPB analogues, and other compounds of such function described in the state of art can be used, whilst as CysLTRl antagonists, in addition to montelukast or zafirlukast, also pranlukast can be used as well as other compounds of such function disclosed in the state of the art. It should be noted that using only an inhibitor or only an antagonist leads to only induction of differentiation or only to inhibition of invasiveness, respectively. In addition, it should be emphasized that such a solution is not obvious, and it is possible only in the case of cancer cells that are characterized by an increased ability to secrete leukotriene. Cells that meet these criteria are cells in the invasive stages of tumor development. They secrete more LTC4, which is converted to LTD4 by GGT1 protein. Subsequently, LTD4 binds to CysLTRl, increasing the ability of cells to invade. Thus, the application of the combination comprising the GGT1 inhibitor and the CysLTRl antagonist causes: (a) on the one hand, inhibition of the pathway responsible for inducing the cell invasiveness (by blocking the interaction of LTD4 and CysLTRl), (b) on the other hand, a stimulation of cell differentiation, i.e., cell transformation to a less advanced stage (by increasing the LTC4 level, and consequently stimulating the LTC4- CysLTR2 interaction).
The subject of the invention is a combination comprising a gamma-glutamyltransferase 1 (GGT1) protein inhibitor and a cysteinyl type 1 receptor (CysLTRl) antagonist.
Preferably the GGT1 protein inhibitor is selected from the group comprising: acivicin, 6-diazo- 5-oxo-L-nor-leucine, azaserine, OU749, GGsTop, GGTI-DU40 and its analogues, 26S -amino- 4-azi do-butanoic acid, y-phosphono monoester of glutamate and its analogues, y-phosphono diester of glutamate and its analogues, L-ABBA and its analogues, glutathione-analogous peptidyl phosphorus esters, phospho-glutathione ACPB analogues.
Preferably the CysLTRl antagonist is selected from the group comprising: montelukast, zafirlukast and pranlukast.
Preferably the GGT1 protein inhibitor is selected from acivicin and 6-diazo-5-oxo-L- norleucine, and the CysLTRl antagonist is selected from montelukast and zafirlukast. Further subject of the invention is the combination according to the invention for use in the treatment of invasive stages of cancer.
Preferably the cancer is colorectal cancer.
Preferably treatment is a supportive treatment in chemotherapy or radiotherapy.
Preferred features of the present invention are illustrated by the following drawings that supplement the information provided in the embodiments.
Description of the drawings
Fig. 1 The effect of leukotriene on the invasiveness of colorectal cancer cells. (A) Colorectal cancer cells isolated from patients with different colon cancer invasive stages were grown in a culture vessel for 48 hours, and then the level of leukotriene secreted by the cells into the medium was determined by the ELISA assay. The graphs display mean ± S.D. (n=4). (B) SW620 cells were stimulated with increasing leukotriene concentrations for 48 hours, and then the ability of the cells to invade was determined. The graphs display mean ± S.D. (n=3).
Fig. 2 The effect of GGT1 inhibitors on modulating the differentiation process of colorectal cancer cells and their invasion abilities. Colorectal cancer cells isolated from patients with different colon cancer invasive stages were treated with IpM of GGT1 inhibitors: ACV (acivicin) or DON (6-diazo-5-oxo-L-norleucine) for 48 hours, followed by a determination of (A) the level of the mucin 2 (MUC2) which is a marker of differentiation of colorectal cancer cells, (B) the ability of the cells to invade. The graphs display mean ± S.D. (n=3).
Fig. 3 The effect of reducing the GGT1 protein level on the differentiation of colorectal cancer cells. (A) The GGT1 protein level was determined in colorectal cancer cells isolated from patients with different colon cancer invasive stages by the Western Blot techniques. The protein level was normalized to GAPDH. The graphs display mean ± S.D. (n=3). (B) The effectiveness of GGT1 silencing in LoVo cells was confirmed by the WB assay. The GGT1 protein level was normalized to GAPDH. The graphs display mean ± S.D. (n=3). (C) GGT1 was downregulated with siRNA in colon cancer cells with different invasiveness properties, followed by a determination of the level of mucin 2 (MUC2), which is a marker of differentiation of colorectal cancer cells. The graphs display mean ± S.D. (n=3).
Fig. 4 The effect of CysLTRl antagonists on modulating colon cancer cells invasion abilities and their differentiation. Colorectal cancer cells isolated from patients with different colon cancer invasive stages were treated with lOpM of CysLTRl antagonists: MON (montelukast) or ZAF (zafirlukast) for 48 hours, followed by a determination of (A) the ability of the cells to invade, (B) the level of the mucin 2 (MUC2) which is a marker of differentiation of colorectal cancer cells. The graphs display mean ± S.D. (n=3).
Fig. 5 The effect of the simultaneous use of the GGT1 inhibitors and the CysLTRl antagonists on modulating the differentiation process of colorectal cancer cells and their invasion abilities. Colorectal cancer cells isolated from patients with different colon cancer invasive stages were treated with IpM of ACV (acivicin) alone, or in combination with lOpM of MON (montelukast) or ZAF (zafirlukast); or IpM of DON (6-diazo-5-oxo-L-norleucine) alone, or in combination with lOpM of MON (montelukast) or ZAF (zafirlukast) for 48 hours, followed by a determination of (A) the level of the mucin 2 (MUC2) which is a marker of differentiation of colorectal cancer cells, (B) the ability of the cells to invade. The graphs display mean ± S.D. (n=3).
EXAMPLES
General procedures used
In the described examples, an analysis was performed using cell lines isolated from various stages of colorectal cancer development: SW620 (a model of cells with a lower invasive potential) and LoVo (a model of cells with a higher invasive potential). The cells lines were cultured as a monolayer and maintained in DMEM with GlutaMAX™ supplemented with 10% (v/v) fetal bovine serum (FBS), penicillin (100 U/mL), and streptomycin (100 pg/mL) in an incubator under standard conditions (temperature of 37°C, CO2 concentration of 5%, relative humidity of 85%),). Cells were cultured in a logarithmic growth phase and preventing them from reaching of confluence. The protein level in the cell lines was estimated by the Western Blot technique. Silencing the GGT1 gene expression and consequently reducing the GGT1 protein level was performed by the interfering RNA (siRNA) technique using the Xfect® Reagent from TakaraBio according to the manufacturer's instructions. The leukotriene level was analyzed by the commercially available ELISA assay (Leukotriene C4 ELISA Kit) according to the manufacturer's instructions. Moreover, the invasive potential of the studied cell lines was determined based on an analysis of the ability of the cells to transmigrate to a chemoattractant (20% FBS) through a Matrigel-covered membrane with 8.0 pm pores. The ability of the cells to differentiate was determined based on investigating the changes in the level of MUC2 (a marker of differentiation of colorectal cancer cells) by immunofluorescence staining. The cells were washed with PBS, fixed (4% formaldehyde in a PHEM buffer, 20 min at RT), permeabilized (0.1% Triton X-100 in a PHEM buffer, 5 min at 4°C), and then labelled with antibodies (incubated with mucin-2-recognizing antibodies, 2h at 37°C; then with secondary antibodies conjugated to the Alexa488 fluorescent dye for Ih at RT). The staining was visualized with EVOS FLoid Imaging Station and analyzed using Imaged software.
Example 1. Testing the effect of leukotriene on invasive abilities induction in colorectal cancer cells.
The cells were seeded onto a 6-well plate, and after a 24-hour incubation, the culture medium was changed to a fresh one. After a 48-hour culture under standard conditions (temperature of 37°C, CO2 concentration of 5%, relative humidity of 85%), the level of the leukotriene secreted into the medium was measured by the ELISA assay. LoVo cells, isolated from a metastatic colorectal cancer (Dukes' D Class), secreted about 8 times more leukotriene than the SW620 cells, which had been isolated from the lymph node (Dukes' C Class), as shown in Fig. 1A. Next, the effect of leukotriene on inducing the invasiveness in the SW620 cells was determined. Cells were treated with increasing doses of leukotriene (0.5, 1, and 2nM) for 48- hour. Then, the invasive abilities of the cells were determined as described above. It was observed that leukotriene stimulated the invasion abilities of colon cancer cells in a concentration-dependent manner, as shown in Fig. IB.
Example 2, Testing the effect of the inhibition of the GGT1 protein activity on the differentiation of colorectal cancer cells. The cells were seeded onto a 6-well plate, and after a 24-hour incubation, the culture medium was changed to a fresh one. Then, cells were treated with IpM of acivicin or 6-diazo- 5-oxo-L-norleucine and after a 48-hour of incubation, an immunocytochemical assay of the level of MUC2 was performed as described above. The results are shown in Fig. 2A. GGT1 inhibition by acivicin resulted in a 4- and 6,5-fold increase in MUC2 for SW620 and LoVo, respectively. 6-diazo-5-oxo-L-norleucine caused a 2.7- and 11.1-fold increase in MUC2 for SW620 and LoVo, respectively.
Example 3, Testing the effect of the inhibition of the GGT1 protein activity on the invasiveness of colorectal cancer cells.
The cells were seeded onto a 6-well plate, and after a 24-hour incubation, the culture medium was changed to a fresh one. Then, cells were treated with IpM of acivicin or 6-diazo- 5-oxo-L-norleucine, and after a 48-hour of incubation, the invasion potential of studied cell lines was estimated, as described above. The results are shown in Fig. 2B. None of the tested inhibitors affected the invasive potential of the studied cells.
Example 4, Testing the effect of reducing the GGT1 protein level on the differentiation of colorectal cancer cells.
The GGT1 protein level was determined in colorectal cancer cells isolated from patients with different colon cancer invasive stages: SW620 (a low invasiveness potential) and LoVo (a high invasiveness potential). It was observed (Fig. 3 A) that the GGT1 protein level was higher in the cells with a high invasiveness potential (LoVo).
It was also checked whether a reduction in the GGT1 protein level would affect the differentiation of colorectal cancer cells. The cells were seeded onto a 6-well plate, and after a 24-hour incubation, the culture medium was changed to a fresh one and the GGT1 gene expression was silenced for 48 hours by the small interfering RNA technique as described above. The silencing efficiency of GGT1 was about 80% (Fig. 3B).Then, the MUC2 level was determined immunocytochemically, as described above. The GGT1 downregulation increased the MUC2 level by 3.7-fold and 11.3-fold in SW620 and LoVo, respectively (Fig. 3C).
Example 5, Testing the effect of the CysLTRl antagonists on the invasiveness of colorectal cancer cells.
The cells were seeded onto a 6-well plate, and after a 24-hour incubation, the culture medium was changed to a fresh one. Then, cells were treated with 10 pM of CysLTRl antagonists: montelukast or zafirlukast and after a 48-hour of incubation the invasion potential of studied cell lines was estimated, as described above. The results are shown in Fig. 4A. Both antagonists showed a similar effect against LoVo, resulting in a nearly 8-fold decrease in the invasion abilities of cells. None of the tested inhibitors affected the invasive potential of SW620 cells.
Example 6, Testing the effect of the CysLTRl antagonists on the differentiation of colorectal cancer cells.
The cells were seeded onto a 6-well plate, and after a 24-hour incubation, the culture medium was changed to a fresh one. Then, cells were treated with 10 pM of CysLTRl antagonists: montelukast or zafirlukast and after a 48-hour of incubation, an immunocytochemical assay of the level of MUC2 was performed, as described above. The results are shown in Fig. 4B. None of the tested antagonists affected the MUC2 level in the studied cell lines.
Example 7, Testing the effect of the simultaneous use of the GGT1 protein inhibitors and the CysLTRl leukotriene receptor antagonists on the differentiation of colorectal cancer cells and on the inhibition of the invasiveness of colorectal cancer cells.
The cells were seeded onto a 6-well plate, and after a 24-hour incubation, the culture medium was changed to a fresh one. Then, cells were treated with IpM of acivicin (GGT1 inhibitor) alone or in combination with a 10 pM of CysLTRl antagonist, montelukast or zafirlukast; or with IpM of 6-diazo-5-oxo-L-norleucine (GGT-1 inhibitor) alone or in combination with a 10 pM of CysLTRl antagonist, montelukast or zafirlukast. After a 48-hour incubation, an immunocytochemical assay of the level of MUC2 and the invasion potential of studied cell lines were estimated, as described above. The results are shown in Fig. 5.
The mixture of the GGT1 protein inhibitor - acivicin together with the CysLTRl antagonist: montelukast or zafirlukast was observed to cause the level of MUC2 in the treated cells to increase to the level which was observed in the case of the use of acivicin alone. Moreover, in the case of the LoVo cells, a 2.7- and 4.5-fold reduction in the invasive potential of the cells were observed for the combination of acivicin with montelukast and zafirlukast, respectively. However, no change in the effect on the invasive potential of SW620 cells was observed after using the combination of acivicin with montelukast or zafirlukast. Moreover, acivicin alone did not affect the invasive potential of the cells. A similar level of change as for the combination of acivicin with montelukast or zafirlukast was observed for the mixture of another GGT1 protein inhibitor, 6-diazo-5-oxo-L-nor-leucine together with the CysLTRl antagonist montelukast or zafirlukast.
References:
[1], Magnusson C, Mezhybovska M, Lbrinc E, Fernebro E, Nilbert M, Sjblander A. Low expression of CysLTIR and high expression of CysLT2R mediate good prognosis in colorectal cancer. Eur J Cancer. 2010 Mar;46(4):826-35.
[2], Magnusson C, Liu J, Ehrnstrbm R, Manjer J, Jirstrbm K, Andersson T, Sjblander A. Cysteinyl leukotriene receptor expression pattern affects migration of breast cancer cells and survival of breast cancer patients. Int J Cancer. 2011 Jul l;129(l):9-22.
[3], Compton CC. Colorectal carcinoma: diagnostic, prognostic, and molecular features. Mod Pathol. 2003 Apr;16(4):376-88.
[4], Derwinger K, Kodeda K, Bexe-Lindskog E, Taflin H. Tumour differentiation grade is associated with TNM staging and the risk of node metastasis in colorectal cancer. Acta Oncologica, 2010; 49: 57-62
[5], Magnusson C, Ehrnstrbm R, Olsen J, Sjblander A. An increased expression of cysteinyl leukotriene 2 receptor in colorectal adenocarcinomas correlates with high differentiation. Cancer Res. 2007 Oct l;67(19):9190-8. [6], Li C, Zuo D, Yin L, Lin Y, Li C, Liu T, Wang L. Prognostic Value of MUC2 Expression in Colorectal Cancer: A Systematic Review and Meta- Analysis. Gastroenterol Res Pract. 2018 Jun 5;2018:6986870.
[7], Li C, Zuo D, Liu T, Yin L, Li C, Wang L. Prognostic and Clinicopathological Significance of MUC Family Members in Colorectal Cancer: A Systematic Review and Meta- Analysis. Gastroenterol Res Pract. 2019 Dec 20;2019:2391670.
[8], Bengtsson AM, Jonsson G, Magnusson C, Salim T, Axelsson C, Sjblander A. The cysteinyl leukotriene 2 receptor contributes to all-trans retinoic acid-induced differentiation of colon cancer cells. BMC Cancer. 2013 Jul 8; 13:336.

Claims

Claims A combination comprising a gamma-glutamyltransferase 1 (GGT1) protein inhibitor and a cysteinyl type 1 receptor (CysLTRl) antagonist. The combination according to claim 1 characterised in that the GGT1 protein inhibitor is selected from the group comprising: acivicin, 6-diazo-5-oxo-L-nor-leucine, azaserine, OU749, GGsTop, GGTI-DU40 and its analogues, 26S -amino-4-azido- butanoic acid, y-phosphono monoester of glutamate and its analogues, y-phosphono diester of glutamate and its analogues, L-ABBA and its analogues, glutathione- analogous peptidyl phosphorus esters, phospho-glutathione ACPB analogues. The combination according to claim 1 or 2 characterized in that the CysLTRl antagonist is selected from the group comprising: montelukast, zafirlukast and pranlukast. The combination according to claim 1 or 2 or 3, characterized in that the GGT1 protein inhibitor is selected from acivicin and 6-diazo-5-oxo-L-norleucine, and the CysLTRl antagonist is selected from montelukast and zafirlukast. The combination as defined in any one of claims 1-4 for use in the treatment of invasive stages of cancer. The combination according to claim 5, characterized in that the cancer is colorectal cancer. The combination according to claim 5, characterized in that the treatment is a supportive treatment in chemotherapy or radiotherapy.
EP23753962.2A 2022-07-22 2023-07-12 Combination comprising a ggt1 inhibitor and a cysltr1 antagonist and use thereof in the treatment of invasive stages of cancer Pending EP4558139A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
PL441816A PL441816A1 (en) 2022-07-22 2022-07-22 Pharmaceutical composition containing a GGT1 protein inhibitor and a CysLTR1 receptor antagonist and its use in the treatment of invasive stages of cancer
PCT/IB2023/057151 WO2024018334A1 (en) 2022-07-22 2023-07-12 Combination comprising a ggt1 inhibitor and a cysltr1 antagonist and use thereof in the treatment of invasive stages of cancer

Publications (1)

Publication Number Publication Date
EP4558139A1 true EP4558139A1 (en) 2025-05-28

Family

ID=87569894

Family Applications (1)

Application Number Title Priority Date Filing Date
EP23753962.2A Pending EP4558139A1 (en) 2022-07-22 2023-07-12 Combination comprising a ggt1 inhibitor and a cysltr1 antagonist and use thereof in the treatment of invasive stages of cancer

Country Status (3)

Country Link
EP (1) EP4558139A1 (en)
PL (1) PL441816A1 (en)
WO (1) WO2024018334A1 (en)

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008137446A1 (en) * 2007-05-03 2008-11-13 Trustees Of Boston University Methods and compositions for the treatment of respiratory disease
US8741937B2 (en) * 2008-02-04 2014-06-03 The Board Of Regents Of The University Of Oklahoma Gamma glutamyl transpeptidase inhibitors and methods of use
CN108135875B (en) * 2015-07-31 2021-12-31 约翰霍普金斯大学 Methods and compositions for treating metabolic reprogramming disorders

Also Published As

Publication number Publication date
PL441816A1 (en) 2024-01-29
WO2024018334A1 (en) 2024-01-25

Similar Documents

Publication Publication Date Title
Yang et al. RRM2 protects against ferroptosis and is a tumor biomarker for liver cancer
Wang et al. RNA binding protein DAZAP1 promotes HCC progression and regulates ferroptosis by interacting with SLC7A11 mRNA
Han et al. A reciprocal feedback between colon cancer cells and Schwann cells promotes the proliferation and metastasis of colon cancer
Liu et al. Retracted article: Exosome-transmitted miR-128-3p increase chemosensitivity of oxaliplatin-resistant colorectal cancer
Fu et al. Exosomal TRIM3 is a novel marker and therapy target for gastric cancer
Kabir et al. A miR-335/COX-2/PTEN axis regulates the secretory phenotype of senescent cancer-associated fibroblasts
Terry et al. Cross modulation between the androgen receptor axis and protocadherin-PC in mediating neuroendocrine transdifferentiation and therapeutic resistance of prostate cancer
Yu et al. O-GlcNAcylation of ITGA5 facilitates the occurrence and development of colorectal cancer
Shao et al. Downregulation of miR-221–3p promotes the ferroptosis in gastric cancer cells via upregulation of ATF3 to mediate the transcription inhibition of GPX4 and HRD1
Wu et al. The mechanism of selenium regulating the permeability of vascular endothelial cells through selenoprotein O
Li et al. Circ_0001955 acts as a miR-646 sponge to promote the proliferation, metastasis and angiogenesis of hepatocellular carcinoma
Xia et al. MAT2A inhibits the ferroptosis in osteosarcoma progression regulated by miR-26b-5p
Fang et al. CircRNA circTRAF3 promotes nasopharyngeal carcinoma metastasis through targeting miR-203a-3p/AKT3 axis
Wang et al. CAPG facilitates diffuse large B-cell lymphoma cell progression through PI3K/AKT signaling pathway
Ren et al. TSP‐1 is downregulated and inversely correlates with miR‐449c expression in Cushing's disease
Wang et al. C1QBP regulates apoptosis of renal cell carcinoma via modulating xanthine dehydrogenase (XDH) mediated ROS generation
Wen et al. Investigating the role of exosomal microRNA-5703 in modulating tumor-associated endothelial cells in lung cancer
Zhong et al. PCMT1 regulates the migration, invasion, and apoptosis of prostate cancer through modulating the PI3K/AKT/GSK-3β pathway
He et al. Ubiquitylation of RUNX3 by RNA-binding ubiquitin ligase MEX3C promotes tumorigenesis in lung adenocarcinoma
Zhao et al. LncRNA FOXD3-AS1/miR-128-3p axis-mediated IGF2BP3 in glioma stimulates cancer angiogenesis and progression
Yu et al. STAM binding protein regulated by hsa_circ_0007334 exerts oncogenic potential in pancreatic cancer
Piao et al. SerpinB2 deficiency is associated with delayed mammary tumor development and decreased pro-tumorigenic macrophage polarization
Qin et al. Osteoglycin (OGN) promotes tumorigenesis of pancreatic cancer cell via targeting ID4
Guo et al. LINC01146/F11R facilitates growth and metastasis of prostate cancer under the regulation of TGF-β
EP4558139A1 (en) Combination comprising a ggt1 inhibitor and a cysltr1 antagonist and use thereof in the treatment of invasive stages of cancer

Legal Events

Date Code Title Description
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: UNKNOWN

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20250217

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC ME MK MT NL NO PL PT RO RS SE SI SK SM TR

DAV Request for validation of the european patent (deleted)
DAX Request for extension of the european patent (deleted)